NextCure (NXTC) Competitors $5.13 +0.02 (+0.39%) Closing price 03:52 PM EasternExtended Trading$5.12 -0.01 (-0.19%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock NXTC vs. UNCY, DTIL, PDSB, ELYM, KLRS, ANVS, PYRGF, PRLD, CVM, and INKTShould you be buying NextCure stock or one of its competitors? The main competitors of NextCure include Unicycive Therapeutics (UNCY), Precision BioSciences (DTIL), PDS Biotechnology (PDSB), Eliem Therapeutics (ELYM), Kalaris Therapeutics (KLRS), Annovis Bio (ANVS), PyroGenesis Canada (PYRGF), Prelude Therapeutics (PRLD), CEL-SCI (CVM), and MiNK Therapeutics (INKT). These companies are all part of the "pharmaceutical products" industry. NextCure vs. Its Competitors Unicycive Therapeutics Precision BioSciences PDS Biotechnology Eliem Therapeutics Kalaris Therapeutics Annovis Bio PyroGenesis Canada Prelude Therapeutics CEL-SCI MiNK Therapeutics Unicycive Therapeutics (NASDAQ:UNCY) and NextCure (NASDAQ:NXTC) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, institutional ownership, earnings, profitability, valuation and media sentiment. Does the media prefer UNCY or NXTC? In the previous week, Unicycive Therapeutics had 28 more articles in the media than NextCure. MarketBeat recorded 28 mentions for Unicycive Therapeutics and 0 mentions for NextCure. Unicycive Therapeutics' average media sentiment score of 0.28 beat NextCure's score of 0.00 indicating that Unicycive Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Unicycive Therapeutics Neutral NextCure Neutral Which has more risk & volatility, UNCY or NXTC? Unicycive Therapeutics has a beta of 1.88, suggesting that its stock price is 88% more volatile than the S&P 500. Comparatively, NextCure has a beta of 1.25, suggesting that its stock price is 25% more volatile than the S&P 500. Do insiders and institutionals hold more shares of UNCY or NXTC? 40.4% of Unicycive Therapeutics shares are held by institutional investors. Comparatively, 42.7% of NextCure shares are held by institutional investors. 10.7% of Unicycive Therapeutics shares are held by company insiders. Comparatively, 17.9% of NextCure shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Is UNCY or NXTC more profitable? NextCure's return on equity of -106.62% beat Unicycive Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Unicycive TherapeuticsN/A -243.13% -119.46% NextCure N/A -106.62%-85.20% Which has preferable earnings & valuation, UNCY or NXTC? Unicycive Therapeutics has higher revenue and earnings than NextCure. Unicycive Therapeutics is trading at a lower price-to-earnings ratio than NextCure, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioUnicycive Therapeutics$680K78.07-$36.73M-$4.12-1.02NextCureN/AN/A-$55.65M-$25.82-0.20 Do analysts rate UNCY or NXTC? Unicycive Therapeutics presently has a consensus target price of $60.00, suggesting a potential upside of 1,328.57%. NextCure has a consensus target price of $25.50, suggesting a potential upside of 397.08%. Given Unicycive Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Unicycive Therapeutics is more favorable than NextCure.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Unicycive Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33NextCure 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 SummaryUnicycive Therapeutics beats NextCure on 9 of the 14 factors compared between the two stocks. Get NextCure News Delivered to You Automatically Sign up to receive the latest news and ratings for NXTC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NXTC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NXTC vs. The Competition Export to ExcelMetricNextCureMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$13.75M$3.09B$5.82B$9.74BDividend YieldN/A2.23%3.84%4.09%P/E Ratio-0.2021.1431.1525.97Price / SalesN/A399.83475.57123.18Price / CashN/A43.0937.1558.38Price / Book0.438.079.116.39Net Income-$55.65M-$54.72M$3.26B$265.66M7 Day Performance0.69%2.62%2.11%1.98%1 Month Performance4.27%7.63%5.12%1.33%1 Year Performance-72.94%13.11%31.25%21.15% NextCure Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NXTCNextCure4.1154 of 5 stars$5.13+0.4%$25.50+397.1%-74.2%$13.75MN/A-0.2090UNCYUnicycive Therapeutics2.7045 of 5 stars$4.01-2.0%$60.00+1,396.3%+13.0%$51.70M$680K-0.799Trending NewsDTILPrecision BioSciences4.1696 of 5 stars$4.35-0.7%$47.00+980.5%-51.8%$51.63M$68.70M-0.49200Positive NewsPDSBPDS Biotechnology2.1989 of 5 stars$1.08-2.7%$9.00+733.3%-67.0%$50.74MN/A-1.1520ELYMEliem TherapeuticsN/A$1.70+1.2%N/A-63.0%$50.58MN/A-3.219News CoveragePositive NewsKLRSKalaris Therapeutics1.3201 of 5 stars$2.66-0.4%$3.00+12.8%N/A$49.94MN/A0.00110Gap UpANVSAnnovis Bio2.5902 of 5 stars$2.82+10.6%$18.00+538.3%-75.2%$49.69MN/A-1.313PYRGFPyroGenesis CanadaN/A$0.26-5.4%N/A-65.9%$49.68M$9.14M-4.4290Gap UpPRLDPrelude Therapeutics2.9166 of 5 stars$0.83-3.6%$4.50+444.1%-79.5%$48.42M$7M-0.49120CVMCEL-SCI1.461 of 5 stars$7.03-5.5%N/A-73.1%$48.38MN/A-14.6543INKTMiNK Therapeutics2.8494 of 5 stars$12.22+1.3%$37.50+206.9%+78.1%$48.07MN/A-4.8530Trending NewsAnalyst Revision Related Companies and Tools Related Companies UNCY Competitors DTIL Competitors PDSB Competitors ELYM Competitors KLRS Competitors ANVS Competitors PYRGF Competitors PRLD Competitors CVM Competitors INKT Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NXTC) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon Musk’s New TechnologyElon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a n...Paradigm Press | SponsoredNew law could create $3.7 trillion tsunami.During a meeting in Washington D.C., Jeff Brown discovered a bold initiative. He calls it “President Trump’...Brownstone Research | SponsoredA grave, grave error.Nvidia just shattered records—hitting $4 trillion in valuation faster than any company in history. But one ...Porter & Company | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NextCure, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NextCure With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access